Tarlatumab represents a landmark achievement in a field with many failures. It is the only drug for second-line small cell lung cancer (SCLC) to ever demonstrate superiority over a therapeutic control arm (chemotherapy) in a randomized trial, improving survival, toxicity, and symptoms.
While the antibody-drug conjugate Rova-T ultimately failed due to toxicity and efficacy issues, it was not a total loss. Its development laid the groundwork for future therapies by demonstrating that DLL3 is a legitimate, targetable antigen on SCLC cells, which paved the way for tarlatumab's success.
Emerging data suggests SCLC molecular subtypes (e.g., ASCL1, POU2F3) correlate with tarlatumab response. However, this research is too premature to guide clinical decision-making. Clinicians are strongly cautioned against altering patient management based on this "intriguing but not yet proven" subtype data.
Real-world data shows higher rates of cytokine release syndrome (CRS) with tarlatumab than trials reported, especially in sicker patients. Despite this, the drug's risk-benefit profile is often better than chemotherapy for poor-performance patients, sometimes leading to durable, life-changing outcomes where no other options exist.
Recent NCCN guidelines have fundamentally changed second-line SCLC treatment. The previous standard, which based treatment on a >6 or <6 month chemotherapy-free interval, has been eliminated. Tarlatumab is now the single, category-one recommended therapy for all second-line patients, regardless of prior treatment timing.